Advances in Thyroid Gland Regeneration: The Integrated Approach of Cell Biology and Bioengineering.

IF 4.3 2区 医学 Q2 CELL & TISSUE ENGINEERING
Tomasz Górnicki, Maria Grazia Soriano, Giuseppe Raffaele, Gabriele Maria Fortunato, Walis Jones, Antonella Cecchettini, Patrycja Szymczyk-Ziółkowska, Krzysztof Kaliszewski, Piotr Dzięgiel, Federico Vozzi, Carmelo Di Maria, Bartosz Kempisty, Giovanni Vozzi
{"title":"Advances in Thyroid Gland Regeneration: The Integrated Approach of Cell Biology and Bioengineering.","authors":"Tomasz Górnicki, Maria Grazia Soriano, Giuseppe Raffaele, Gabriele Maria Fortunato, Walis Jones, Antonella Cecchettini, Patrycja Szymczyk-Ziółkowska, Krzysztof Kaliszewski, Piotr Dzięgiel, Federico Vozzi, Carmelo Di Maria, Bartosz Kempisty, Giovanni Vozzi","doi":"10.1177/19373368261431206","DOIUrl":null,"url":null,"abstract":"<p><p>The thyroid gland is an endocrine organ responsible for production of triiodothyronine and thyroxine, essential hormones that regulate human metabolism. A wide range of conditions can impair its function, leading to potential life-threatening consequences such as myxedema coma. The standard treatment for hypothyroidism is lifelong levothyroxine supplementation, which, despite being a significant therapeutic breakthrough, has notable limitations and does not fully restore quality of life for many patients. Biomimetic thyroid gland has emerged as a promising alternative treatment strategy for patients with hypothyroidism. Most research to date has focused on generating thyroid organoids from primary thyroid cells or stem cells. However, there is growing interest in other approaches, including the use of biomaterials, bioreactors, and 3D bioprinting as potential alternatives or supplementary technologies to the organoids. While <i>in vitro</i> and preclinical studies have shown encouraging results, clinical application of biomimetic thyroid gland requires further studies in several key areas, including long-term functional validation, studies on large animal models, immunological compatibility and scaffold biodegradation, and absence of standardized good manufacturing practice (GMP)-compliant production protocols.</p>","PeriodicalId":23134,"journal":{"name":"Tissue Engineering. Part B, Reviews","volume":" ","pages":"19373368261431206"},"PeriodicalIF":4.3000,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tissue Engineering. Part B, Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/19373368261431206","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0

Abstract

The thyroid gland is an endocrine organ responsible for production of triiodothyronine and thyroxine, essential hormones that regulate human metabolism. A wide range of conditions can impair its function, leading to potential life-threatening consequences such as myxedema coma. The standard treatment for hypothyroidism is lifelong levothyroxine supplementation, which, despite being a significant therapeutic breakthrough, has notable limitations and does not fully restore quality of life for many patients. Biomimetic thyroid gland has emerged as a promising alternative treatment strategy for patients with hypothyroidism. Most research to date has focused on generating thyroid organoids from primary thyroid cells or stem cells. However, there is growing interest in other approaches, including the use of biomaterials, bioreactors, and 3D bioprinting as potential alternatives or supplementary technologies to the organoids. While in vitro and preclinical studies have shown encouraging results, clinical application of biomimetic thyroid gland requires further studies in several key areas, including long-term functional validation, studies on large animal models, immunological compatibility and scaffold biodegradation, and absence of standardized good manufacturing practice (GMP)-compliant production protocols.

甲状腺再生的研究进展:细胞生物学与生物工程的结合。
甲状腺是一个内分泌器官,负责产生三碘甲状腺原氨酸和甲状腺素,这是调节人体新陈代谢的必要激素。多种情况可损害其功能,导致潜在的危及生命的后果,如黏液水肿昏迷。甲状腺功能减退的标准治疗是终生补充左甲状腺素,尽管这是一项重大的治疗突破,但仍有明显的局限性,并不能完全恢复许多患者的生活质量。仿生甲状腺已成为甲状腺功能减退症患者的一种有希望的替代治疗策略。迄今为止,大多数研究都集中在从原代甲状腺细胞或干细胞中产生甲状腺类器官。然而,人们对其他方法的兴趣越来越大,包括使用生物材料、生物反应器和3D生物打印作为类器官的潜在替代品或补充技术。虽然体外和临床前研究显示出令人鼓舞的结果,但仿生甲状腺的临床应用还需要在几个关键领域进行进一步的研究,包括长期功能验证、大型动物模型研究、免疫相容性和支架生物降解,以及缺乏标准化的GMP生产规程。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Tissue Engineering. Part B, Reviews
Tissue Engineering. Part B, Reviews Biochemistry, Genetics and Molecular Biology-Biochemistry
CiteScore
12.80
自引率
1.60%
发文量
150
期刊介绍: Tissue Engineering Reviews (Part B) meets the urgent need for high-quality review articles by presenting critical literature overviews and systematic summaries of research within the field to assess the current standing and future directions within relevant areas and technologies. Part B publishes bi-monthly.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书